1 / 40

Dallas Heart Study Lipid Characteristics of Blacks With Nonsense Mutations in PCSK9

Dallas Heart Study Lipid Characteristics of Blacks With Nonsense Mutations in PCSK9. ARIC PCSK9 Loss-of-Function Mutations, LDL-C, and CHD Risk. PCSK9-Directed Therapies in Development. Effects of Evolocumab (AMG-145) on LDL-C Levels Phase 1b Study Design.

hamish-cummings
Download Presentation

Dallas Heart Study Lipid Characteristics of Blacks With Nonsense Mutations in PCSK9

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Dallas Heart StudyLipid Characteristics of Blacks With Nonsense Mutations in PCSK9

  2. ARICPCSK9 Loss-of-Function Mutations, LDL-C, and CHD Risk

  3. PCSK9-Directed Therapies in Development

  4. Effects of Evolocumab (AMG-145) on LDL-C LevelsPhase 1b Study Design

  5. Evolocumab -- Phase 1bChange in LDL-C at 2- and 4-Week Dosing Intervals on Statin Therapy

  6. PCSK9 InhibitorsPhase 2

  7. MENDELEvolocumab Phase 2 Monotherapy in Patients With Hypercholesterolemia

  8. MENDELStudy Design

  9. MENDELEvolocumab Monotherapy for Hypercholesterolemia

  10. PCSK9 InhibitorsPhase 2

  11. Alirocumab (SAR236553) Add-on to Atorvastatin

  12. AlirocumabChange in LDL-C at 2- and 4-Week Dosing Intervals on Atorvastatin

  13. Alirocumab on Top of Atorvastatin in Primary Hypercholesterolemia

  14. LAPLACE-TIMI 57Evolocumab in Combination With Statin in Patients With Hypercholesterolemia

  15. LAPLACE-TIMI 57 Study Design

  16. LAPLACE-TIMI 57 Effect of Evolocumab on Percentage Change in LDL-C From Baseline

  17. Intravenous RN316 in Hypercholesterolemic Patients on High or Maximum-Dose Statin Therapy Phase 2 Studies

  18. Intravenous RN316 in Hypercholesterolemic Patients on High- or Maximum-Dose Statin Therapy Doses Studied

  19. Intravenous RN316 in Hypercholesterolemic Patients on High or Maximum-Dose Statin TherapyPooled Results

  20. PCSK9 InhibitorsPhase 2

  21. GAUSSPhase 2 Evolocumab in Statin-Intolerant Patients

  22. GAUSSEvolocumab in Statin Intolerance

  23. PCSK9 InhibitorsPhase 2

  24. Effect of Alirocumab on LDL-C in Heterozygous FH

  25. RUTHERFORDPhase 2 Evolocumab in Patients With Heterozygous FH

  26. RUTHERFORDEffect of Evolocumab on LDL-C in Heterozygous FH

  27. Phase 3 Trials

  28. OSLER Phase 3 Extension Study

  29. OSLEREffect of Evolocumab on LDL-C after 52 Weeks

  30. ODYSSEY OutcomesPhase 3 Post-ACS With Alirocumab

  31. References

  32. References (cont)

  33. References (cont)

More Related